Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

Blood

Volumn 109, Issue 6, 2007, Pages 2303-2309

  Hochhaus, Andreas ^a   Kantarjian, Hagop M ^b   Baccarani, Michele ^c   Lipton, Jeffrey H ^d   Apperley, Jane F ^e   Druker, Brian J ^f   Facon, Thierry ^g   Goldberg, Stuart L ^h   Cervantes, Francisco ⁱ   Niederwieser, Dietger ^j   Silver, Richard T ^k   Stone, Richard M ^l   Hughes, Timothy P ^m   Muller, Martin C ^a   Ezzeddine, Rana ⁿ   Countouriotis, Athena M ⁿ   Shah, Neil P ^o  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d PRINCESS MARGARET HOSPITAL   (Canada)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^g LILLE UNIVERSITY HOSPITAL   (France)

^h HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

ⁱ HOSPITAL CLÍNIC   (Spain)

^j UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l DANA FARBER CANCER INSTITUTE   (United States)

^m INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

ⁿ BRISTOL MYERS SQUIBB   (United States)

^o UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BILIRUBIN BLOOD LEVEL; BONE PAIN; CANCER SURVIVAL; CARDIOVASCULAR MALFORMATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONGENITAL HEART MALFORMATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; KIDNEY FAILURE; LEUKOPENIA; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; NAUSEA; NEUROPATHY; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PLEURA EFFUSION; PRIORITY JOURNAL; RASH; SIDE EFFECT; STEM CELL TRANSPLANTATION; THROMBOCYTOPENIA; TREATMENT FAILURE;

EID: 33947280081     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-09-047266     Document Type: Article

References (29)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999;340:1330-1340.
2. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2005;105:2640-2653.
3. Hochhaus A, Hughes T. Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am. 2004;18:641-656.
4. Gambacorti C, Talpaz M, Sawyers CL, et al. Five year follow-up results of a phase II trial in patients with late chronic phase (L-CP) chronic myeloid leukemia (CML) treated with imatinib who are refractory/intolerant of interferon-α. Blood. 2005;106:abstract 1089.
5. Druker BJ, Guilhot F, O'Brien S, et al. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study. J Clin Oncol. 2006;24(suppl):abstract 6506.
6. Lahaye T, Riehm B, Berger U, et al. Response and resistance in 300 patients with BCR-ABL-positive leukemias treated with imatinib in a single center: a 4.5-year follow-up. Cancer. 2005;103:1659-1669.
7. Dai Y, Rahmani M, Corey SJ, Dent P, Grant S. A Bcr/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem. 2004;279:34227-34239.
8. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood. 2003;101:690-698.
9. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
10. Mauro M, Deininger M. Chronic myeloid leukemia in 2006: a perspective. Hematologica. 2006;91:152-158.
11. Baccarani M, Saglio J, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemianet. Blood. 2006;108:1809-1820.
12. Tokarski J, Newitt J, Lee F, et al. The crystal structure of Abl kinase with BMS-354825, a dual SRC/ABL kinase inhibitor. Blood. 2004;104:abstract 553.
13. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004;305:399-401.
14. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-4505.
15. Burgess MR, Skaggs BJ, Shah NP, Lee FY, Sawyers CL. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A. 2005;102:3395-3400.
16. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-2541.
17. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics. 1982;38:29-41.
18. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. French Chronic Myeloid Leukemia Study Group. N Engl J Med. 1997;337:223-229.
19. Group ICS. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. N Engl J Med. 1994;330:820-825.
20. Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukemia. Blood Rev. 2006;20:29-41.
21. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117-125.
22. von Bubnoff N, Schneller F, Peschel C, Duyster J. BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study. Lancet. 2002;359:487-491.
23. Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003;102:276-283.
24. Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia. 2006;20:1061-1066.
25. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005;7:129-141.
26. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004;18:401-408.
27. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104:3739-3745.
28. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.
29. Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002;16:2190-2196.